Hoth Therapeutics (HOTH) Competitors $1.32 +0.07 (+5.60%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.30 -0.03 (-1.89%) As of 06/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HOTH vs. BLUE, QNCX, ATRA, ARTV, PEPG, AVTX, IPSC, MRSN, NRXP, and PMVPShould you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include bluebird bio (BLUE), Quince Therapeutics (QNCX), Atara Biotherapeutics (ATRA), Artiva Biotherapeutics (ARTV), PepGen (PEPG), Avalo Therapeutics (AVTX), Century Therapeutics (IPSC), Mersana Therapeutics (MRSN), NRx Pharmaceuticals (NRXP), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry. Hoth Therapeutics vs. Its Competitors bluebird bio Quince Therapeutics Atara Biotherapeutics Artiva Biotherapeutics PepGen Avalo Therapeutics Century Therapeutics Mersana Therapeutics NRx Pharmaceuticals PMV Pharmaceuticals Hoth Therapeutics (NASDAQ:HOTH) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Is HOTH or BLUE more profitable? Hoth Therapeutics has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Hoth Therapeutics' return on equity of -89.68% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets Hoth TherapeuticsN/A -89.68% -82.61% bluebird bio -565.74%-322.46%-53.17% Do insiders and institutionals believe in HOTH or BLUE? 7.1% of Hoth Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 10.6% of Hoth Therapeutics shares are owned by insiders. Comparatively, 1.4% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate HOTH or BLUE? Hoth Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 203.03%. bluebird bio has a consensus price target of $44.60, suggesting a potential upside of 797.38%. Given bluebird bio's higher probable upside, analysts clearly believe bluebird bio is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the MarketBeat Community prefer HOTH or BLUE? bluebird bio received 963 more outperform votes than Hoth Therapeutics when rated by MarketBeat users. Likewise, 70.34% of users gave bluebird bio an outperform vote while only 66.10% of users gave Hoth Therapeutics an outperform vote. CompanyUnderperformOutperformHoth TherapeuticsOutperform Votes7866.10% Underperform Votes4033.90% bluebird bioOutperform Votes104170.34% Underperform Votes43929.66% Which has preferable earnings and valuation, HOTH or BLUE? Hoth Therapeutics has higher earnings, but lower revenue than bluebird bio. Hoth Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoth TherapeuticsN/AN/A-$7.84M-$1.14-1.16bluebird bio$103.95M0.47-$211.91M-$41.32-0.12 Does the media favor HOTH or BLUE? In the previous week, Hoth Therapeutics had 4 more articles in the media than bluebird bio. MarketBeat recorded 5 mentions for Hoth Therapeutics and 1 mentions for bluebird bio. bluebird bio's average media sentiment score of 1.44 beat Hoth Therapeutics' score of -0.03 indicating that bluebird bio is being referred to more favorably in the news media. Company Overall Sentiment Hoth Therapeutics Neutral bluebird bio Positive Which has more risk and volatility, HOTH or BLUE? Hoth Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. SummaryHoth Therapeutics beats bluebird bio on 10 of the 18 factors compared between the two stocks. Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOTH vs. The Competition Export to ExcelMetricHoth TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.44M$6.85B$5.57B$8.61BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-1.008.7827.1720.06Price / SalesN/A255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book0.656.557.064.70Net Income-$7.84M$143.93M$3.23B$247.88M7 Day Performance9.09%3.97%2.89%2.66%1 Month Performance42.07%11.32%9.06%6.40%1 Year Performance33.56%4.20%31.40%14.07% Hoth Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOTHHoth Therapeutics3.4985 of 5 stars$1.32+5.6%$4.00+203.0%+33.6%$17.44MN/A-1.004News CoverageShort Interest ↓BLUEbluebird bio3.3913 of 5 stars$4.96-0.2%$44.60+799.2%N/A$48.57M$103.95M-0.13520Positive NewsHigh Trading VolumeQNCXQuince Therapeutics3.6184 of 5 stars$1.06+1.9%$8.00+654.7%+58.6%$48.20MN/A-0.8560ATRAAtara Biotherapeutics4.3381 of 5 stars$8.00+2.6%$17.75+121.9%-36.6%$47.69M$199.73M-0.31330ARTVArtiva Biotherapeutics2.7093 of 5 stars$1.94+0.5%$19.40+900.0%N/A$47.26M$251K0.0081News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpPEPGPepGen2.7514 of 5 stars$1.44-1.4%$7.67+432.4%-91.9%$47.12MN/A-0.4830Trending NewsAVTXAvalo Therapeutics3.5355 of 5 stars$4.35+8.8%$30.00+589.7%-57.3%$47.10M$441K0.0040News CoverageShort Interest ↓High Trading VolumeIPSCCentury Therapeutics3.0797 of 5 stars$0.54+2.5%$4.20+672.8%-81.4%$46.83M$114.90M-0.29170Positive NewsHigh Trading VolumeMRSNMersana Therapeutics4.1871 of 5 stars$0.37+8.8%$5.20+1,290.7%-83.2%$46.60M$34.01M-0.61150Gap UpNRXPNRx Pharmaceuticals2.0839 of 5 stars$2.68+1.5%$28.50+963.4%+4.8%$46.34MN/A-1.252PMVPPMV Pharmaceuticals2.4001 of 5 stars$0.88-0.1%$5.50+527.1%-34.7%$45.56MN/A-0.8850Positive NewsGap Up Related Companies and Tools Related Companies bluebird bio Alternatives Quince Therapeutics Alternatives Atara Biotherapeutics Alternatives Artiva Biotherapeutics Alternatives PepGen Alternatives Avalo Therapeutics Alternatives Century Therapeutics Alternatives Mersana Therapeutics Alternatives NRx Pharmaceuticals Alternatives PMV Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HOTH) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HOTH Stock Free HOTH Stock Alerts